Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS - Res&Arch Institutional Research Information System - Research &Archive
Background: Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years). Methods: We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis. Findings: 164 563 young people were included in this analysis: 121 328 (73·7%) children, 22 963 (14·0%) adolescents, and 20 272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28 205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries. Interpretation: This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group. Funding: Children with Cancer UK, the Institut National du Cancer, La Ligue Contre le Cancer, Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, Rossy Family Foundation, US National Cancer Institute, and the American Cancer Society.
Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries
Ssenyonga N.;Stiller C.;Nakata K.;Shalkow J.;Redmond S.;Bulliard J. -L.;Girardi F.;Fowler C.;Marcos-Gragera R.;Bonaventure A.;Saint-Jacques N.;Minicozzi P.;De P.;Rodriguez-Barranco M.;Laronningen S.;Di Carlo V.;Magi M.;Valkov M.;Seppa K.;Wyn Huws D.;Coleman M. P.;Allemani C.;Bouzbid S.;Hamdi-Cherif M.;Kara L.;Meguenni K.;Regagba D.;Bayo S.;Cheick Bougadari T.;Manraj S. S.;Bendahhou K.;Ladipo A.;Ogunbiyi O.;Somdyala N.;Chaplin M. A.;Moreno F.;Calabrano G.;Espinola S.;Carballo Quintero B.;Fita R.;Laspada W.;Ibanez S.;Lima C.;Mafra Da Costa A.;De Souza P. C.;Chaves J.;Laporte C.;Curado M. P.;de Oliveira J. C.;Veneziano C.;Veneziano D.;Almeida A. B.;Latorre M.;Azevedo e Silva G.;Rebelo M.;Santos M.;Galaz J.;Aparicio Aravena M.;Sanhueza Monsalve J.;Herrmann D.;Vargas S.;Herrera V.;Uribe C.;Bravo L. E.;Garcia L. S.;Arias-Ortiz N.;Morantes D.;Jurado D.;Yepez Chamorro M.;Delgado S.;Ramirez M.;Galan Alvarez Y.;Torres P.;Martinez-Reyes F.;Jaramillo L.;Quinto R.;Castillo J.;Mendoza M.;Cueva P.;Yepez J.;Bhakkan B.;Deloumeaux J.;Joachim C.;Macni J.;Carrillo R.;Shalkow Klincovstein J.;Rivera Gomez R.;Perez P.;Poquioma E.;Tortolero-Luna G.;Zavala D.;Alonso R.;Barrios E.;Eckstrand A.;Nikiforuk C.;Woods R.;Noonan G.;Turner D.;Kumar E.;Zhang B.;Dowden J.;Doyle G.;Walsh G.;Anam A.;McClure C.;Vriends K.;Bertrand C.;Ramanakumar A.;Kozie S.;Stuart-Panko H.;Freeman T.;George J.;Avila R.;O'Brien D.;Holt A.;Almon L.;Ward K.;Kwong S.;Morris C.;Rycroft R.;Mueller L.;Phillips C.;Brown H.;Cromartie B.;Ruterbusch J.;Schwartz A.;Levin G.;Wohler B.;Bayakly R.;Gomez S.;McKinley M.;Cress R.;Davis J.;Hernandez B.;Johnson C.;Morawski B.;Ruppert L.;Bentler S.;Charlton M.;Huang B.;Tucker T.;Deapen D.;Liu L.;Hsieh M. -C.;Wu X. -C.;Schwenn M.;Stern K.;Gershman S.;Knowlton R.;Alverson G.;Weaver T.;Desai J.;Rogers D.;Jackson-Thompson J.;Lemons D.;Zimmerman H.;Hood M.;Roberts-Johnson J.;Hammond W.;Rees J.;Pawlish K.;Stroup A.;Key C.;Wiggins C.;Kahn A.;Schymura M.;Radhakrishnan S.;Rao C.;Giljahn L.;Slocumb R.;Dabbs C.;Espinoza R.;Aird K.;Beran T.;Rubertone J.;Slack S.;Oh J.;Janes T.;Schwartz S.;Chiodini S.;Hurley D.;Whiteside M.;Rai S.;Williams M.;Herget K.;Sweeney C.;Johnson A.;Keitheri Cheteri M.;Migliore Santiago P.;Blankenship S.;Farley S.;Borchers R.;Malicki R.;Espinoza J.;Grandpre J.;Edwards B.;Mariotto A.;Weir H.;Wilson R.;Wang N.;Yang L.;Chen J. -S.;He Y. -T.;Song G. -H.;Gu X. -P.;Mei D.;Ge H. -M.;Wu T. -H.;Li Y. -Y.;Zhao D. -L.;Jin F.;Zhang J. -H.;Zhu F. -D.;Junhua Q.;Yang Y. L.;Jiang C. -X.;Biao W.;Wang J.;Li Q. -L.;Yi H.;Zhou X.;Dong J.;Li W.;Fu F. -X.;Chen J. -G.;Zhu J.;Li Y. -H.;Lu Y. -Q.;Fan M.;Huang S. -Q.;Guo G. -P.;Zhaolai H.;Wei K.;Chen W. -Q.;Wei W.;Zeng H.;Demetriou A.;Mang W. K.;Ngan K. C.;Kataki A.;Krishnatreya M.;Jayalekshmi P. A.;Sebastian P.;George P.;Mathew A.;Nandakumar A.;Malekzadeh R.;Roshandel G.;Keinan-Boker L.;Silverman B.;Ito H.;Koyanagi Y.;Sato M.;Tobori F.;Nakata I.;Teramoto N.;Hattori M.;Kaizaki Y.;Moki F.;Sugiyama H.;Utada M.;Nishimura M.;Yoshida K.;Kurosawa K.;Nemoto Y.;Narimatsu H.;Sakaguchi M.;Kanemura S.;Naito M.;Narisawa R.;Miyashiro I.;Mori D.;Yoshitake M.;Oki I.;Fukushima N.;Shibata A.;Iwasa K.;Ono C.;Matsuda T.;Nimri O.;Jung K. -W.;Won Y. -J.;Alawadhi E.;Elbasmi A.;Ab Manan A.;Adam F.;Nansalmaa E.;Tudev U.;Ochir C.;Al Khater A. H.;El Mistiri M.;Lim G. H.;Teo Y. Y.;Chiang C. -J.;Lee W. -C.;Buasom R.;Sangrajrang S.;Suwanrungruang K.;Vatanasapt P.;Daoprasert K.;Pongnikorn D.;Leklob A.;Sangkitipaiboon S.;Geater S.;Sriplung H.;Ceylan O.;Kog I.;Dirican O.;Kose T.;Gurbuz T.;Karasahin F. E.;Turhan D.;Aktas U.;Halat Y.;Eser S.;Yakut C.;Altinisik M.;Cavusoglu Y.;Turkkoylu A.;Ucuncu N.;Hackl M.;Zborovskaya A.;Aleinikova O.;Henau K.;Van Eycken L.;Atanasov T.;Valerianova Z.;Sekerija M.;Dusek L.;Zvolsky M.;Steinrud Morch L.;Storm H.;Wessel Skovlund C.;Innos K.;Malila N.;Jegu J.;Velten M.;Cornet E.;Troussard X.;Bouvier A. -M.;Guizard A. -V.;Bouvier V.;Launoy G.;Dabakuyo Yonli S.;Poillot M. -L.;Maynadie M.;Mounier M.;Vaconnet L.;Woronoff A. -S.;Daoulas M.;Robaszkiewicz M.;Clavel J.;Poulalhon C.;Desandes E.;Lacour B.;Baldi I.;Pouchieu C.;Amadeo B.;Coureau G.;Monnereau A.;Audoin M.;D'Almeida T.;Boyer S.;Hammas K.;Tretarre B.;Colonna M.;Delafosse P.;Plouvier S.;Cowppli-Bony A.;Molinie F.;Bara S.;Ganry O.;Lapotre-Ledoux B.;Daubisse-Marliac L.;Bossard N.;Esteve J.;Uhry Z.;Stabenow R.;Wilsdorf-Kohler H.;Eberle A.;Luttmann S.;Lohden I.;Nennecke A.;Kieschke J.;Sirri E.;Justenhoven C.;Zeissig S.;Holleczek B.;Eisemann N.;Katalinic A.;Asquez R.;Kumar V.;Petridou E.;Olafsdottir E.;Tryggvadottir L.;Murray D.;Walsh P.;Sundseth H.;Mazzoleni G.;Vittadello F.;Coviello E.;Cuccaro F.;Galasso R.;Sampietro G.;Magoni M.;Ardizzone A.;D'Argenzio A.;Di Prima A. A.;Ippolito A.;Lavecchia A. M.;Sutera Sardo A.;Gola G.;Ballotari P.;Giacomazzi E.;Ferretti S.;Dal Maso L.;Serraino D.;Celesia M. V.;Filiberti R. A.;Pannozzo F.;Melcarne A.;Quarta F.;Andreano A.;Russo A. G.;Carrozzi G.;Cirilli C.;Cavalieri d'Oro L.;Rognoni M.;Fusco M.;Vitale M. F.;Usala M.;Cusimano R.;Mazzucco W.;Michiara M.;Sgargi P.;Boschetti L.;Chiaranda G.;Seghini P.;Maule M.;Merletti F.;Spata E.;Tumino R.;Mancuso P.;Vicentini M.;Cassetti T.;Sassatelli R.;Falcini F.;Giorgetti S.;Caiazzo A. L.;Cavallo R.;Piras D.;Bella F.;Madeddu A.;Fanetti A. C.;Maspero S.;Carone S.;Mincuzzi A.;Candela G.;Scuderi T.;Gentilini M. A.;Rizzello R.;Rosso S.;Zanetti R.;Caldarella A.;Intrieri T.;Bianconi F.;Stracci F.;Contiero P.;Tagliabue G.;Rugge M.;Zorzi M.;Beggiato S.;Brustolin A.;De Angelis R.;Gatta G.;Maurina A.;Oniscuka M.;Mousavi M.;Lipunova N.;Vincerzevskiene I.;Agius D.;Calleja N.;Siesling S.;Visser O.;Johannesen T.;Trojanowski M.;Mierzwa T.;Rachtan J.;Kepska K.;Koscianska B.;Wojcik-Tomaszewska J.;Motnyk M.;Gos A.;Bielska-Lasota M.;Didkowska J.;Wojciechowska U.;Forjaz de Lacerda G.;Rego R.;Carrito B.;Pais A.;Bento M. J.;Rodrigues J.;Lourenco A.;Mayer-da-Silva A.;Blaga L.;Coza D.;Gusenkova L.;Lazarevich O.;Prudnikova O.;Vjushkov D. M.;Egorova A.;Orlov A.;Pikalova L.;Zhuikova L.;Adamcik J.;Safaei Diba C.;Zadnik V.;Zagar T.;De-La-Cruz M.;Lopez-de-Munain A.;Aleman A.;Rojas D.;Chillaron R. J.;Navarro A. I. M.;Marcos-Gragera R.;Puigdemont M.;Sanchez Perez M. -J.;Franch Sureda P.;Ramos Montserrat M.;Chirlaque Lopez M. D.;Sanchez Gil A.;Ardanaz E.;Guevara M.;Canete-Nieto A.;Peris-Bonet R.;Carulla M.;Galceran J.;Almela F.;Sabater C.;Khan S.;Pettersson D.;Dickman P.;Staehelin K.;Struchen B.;Herrmann C.;Mousavi S. M.;Egger Hayoz C.;Bouchardy C.;Schaffar R.;Went P.;Maspoli-Conconi M.;Kuehni C.;Redmond S.;Bordoni A.;Ortelli L.;Chiolero A.;Konzelmann I.;Rohrmann S.;Wanner M.;Broggio J.;Rashbass J.;Fitzpatrick D.;Gavin A.;Morrison D.;Thomson C.;Greene G.;Huws D.;Coleman M.;Matz M.;Sanz N.;Stephens R.;Chalker E.;Smith M.;Gugusheff J.;You H.;Qin Li S.;Dugdale S.;Moore J.;Philpot S.;Pfeiffer R.;Thomas H.;Silva Ragaini B.;Venn A.;Evans S.;Te Marvelde L.;Savietto V.;Trevithick R.;Currow D.;Lewis C.
2022
Abstract
Background: Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years). Methods: We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis. Findings: 164 563 young people were included in this analysis: 121 328 (73·7%) children, 22 963 (14·0%) adolescents, and 20 272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28 205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries. Interpretation: This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group. Funding: Children with Cancer UK, the Institut National du Cancer, La Ligue Contre le Cancer, Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, Rossy Family Foundation, US National Cancer Institute, and the American Cancer Society.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1546976
Citazioni
5
37
38
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
